# Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults

> **NCT02992119** · PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 193 (actual)

## Conditions studied

- Malaria Vaccine

## Interventions

- **BIOLOGICAL:** RTS,S/AS01B Fractional dose
- **BIOLOGICAL:** Double RTS,S/AS01E Fractional dose
- **BIOLOGICAL:** RTS,S/AS01E Standard dose
- **BIOLOGICAL:** RTS,S/AS01E + DHA-PIP+PQ Standard dose
- **BIOLOGICAL:** RTS,S/AS01E Fractional dose
- **BIOLOGICAL:** RTS,S/AS01E + DHA-PIP+PQ Fractional dose
- **BIOLOGICAL:** RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose

## Key facts

- **NCT ID:** NCT02992119
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-04
- **Primary completion:** 2018-02-20
- **Final completion:** 2018-02-20
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02992119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02992119, "Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02992119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*